The Royal Women's Hospital Pharmacy Department, The Royal Women's Hospital, Parkville, Victoria, Australia.
Hawke's Bay Hospital, Hastings, New Zealand.
Int J Clin Pharm. 2021 Aug;43(4):1006-1014. doi: 10.1007/s11096-020-01209-8. Epub 2020 Nov 24.
Women with substance abuse disorders have lower use of contraception. Unplanned pregnancies increase risk of fetal exposure to addictive and teratogenic substances. Postpartum inpatient periods for these women can be challenging times to facilitate contraception planning.
To explore postnatal contraceptive planning practices, patient preferences for contraception, and supply challenges, and to identify how clinical pharmacists may best provide care in this context.
A tertiary maternity referral hospital in metropolitan Victoria, Australia (January 2015-December 2018).
A retrospective cohort study was conducted on postnatal women with substance abuse disorders. Patients were excluded if they had delivered at another health service, had inadequate documented evidence of a substance abuse disorder, or had incomplete or unavailable medical records. Records were reviewed for demographic data, admission details, and documented contraceptive planning.
Documented contraceptive planning, patient contraception preferences and identified supply challenges.
Ninety-three women were included. Seventy-one (76.3%) had psychiatric disorders or impairments, and 92 (98.9%) had identifiable follow-up challenges (eg. Homelessness). Nine (9.7%) self-discharged/absconded. Eighty-seven (93.5%) had documented postnatal contraception discussions. Sixty-two of 87 (71.3%) considered a medicine/device, three (3.4%) preferred condoms, 10 (11.5%) considered sterilisation, 2 (2.3%) preferred no contraception, and 16 (18.4%) undecided. Etonogestral 68 mg implants were most commonly prescribed (28 of 42; 66.7%).
Inpatient postpartum periods for this cohort were characterised by psycho-social complexities, inconsistent contraceptive planning documentation, and patients seemingly unprepared to consider contraception. This study highlights a need for an earlier decision-making process and pragmatic counselling with antenatal pharmacists.
患有物质滥用障碍的女性使用避孕措施的比例较低。意外怀孕会增加胎儿接触成瘾物质和致畸物质的风险。对于这些女性来说,产后住院期间是促进避孕计划的困难时期。
探讨产后避孕计划实践、患者对避孕方法的偏好以及供应方面的挑战,并确定临床药师在这种情况下如何提供最佳护理。
澳大利亚维多利亚州大都市的一家三级产妇转诊医院(2015 年 1 月至 2018 年 12 月)。
对患有物质滥用障碍的产后妇女进行回顾性队列研究。如果患者在其他医疗机构分娩、有记录的物质滥用障碍证据不足或病历不完整或无法获取,则将其排除在外。对病历进行了人口统计学数据、入院详细信息和记录的避孕计划审查。
记录的避孕计划、患者的避孕偏好和确定的供应挑战。
共纳入 93 名女性。71 名(76.3%)有精神障碍或损伤,92 名(98.9%)有可识别的后续挑战(例如无家可归)。9 名(9.7%)自行出院/逃跑。87 名(93.5%)记录了产后避孕讨论。在 87 名记录避孕讨论的患者中,62 名(71.3%)考虑使用药物/器具避孕,3 名(3.4%)首选避孕套,10 名(11.5%)考虑绝育,2 名(2.3%)首选不避孕,16 名(18.4%)未决定。最常开的是庚酸炔诺酮 68mg 植入剂(28 例;66.7%)。
该队列的产后住院期间的特点是心理社会问题复杂、避孕计划记录不一致,以及患者似乎对考虑避孕没有准备。本研究强调了在产前与药剂师进行更早的决策过程和务实咨询的必要性。